The Paradigm Shift of Neoadjuvant Chemoimmunotherapy in NSCLC

The clinical landscape for resectable non-small cell lung cancer (NSCLC) is currently undergoing a radical transformation. In recent years, neoadjuvant chemoimmunotherapy in NSCLC has emerged as a cornerstone of treatment, aiming to maximize surgical efficacy while minimizing systemic recurrence risks. While clinicians observed improved major pathological response rates, the underlying spatial biology of these responses remained largely enigmatic. Consequently, understanding the complex tumor immune microenvironment is essential for predicting patient outcomes and tailoring adjuvant strategies. This knowledge gap is particularly relevant in the Indian medical context, where lung cancer continues to be a leading cause of mortality. Therefore, researchers are increasingly turning toward advanced spatial profiling techniques to decipher the cellular interactions that dictate therapeutic success or failure. This article explores a recent phase II trial investigating how spatial transcriptomics can inform the management of early-stage lung cancer. By analyzing paired tumor and lymph node samples, this study provides a high-resolution map of the immune shifts induced by neoadjuvant pembrolizumab plus platinum-based chemotherapy. Ultimately, these insights may lead to more personalized oncology pathways for patients across diverse clinical settings.

Insights from the Single-Arm Phase II Trial NCT05383716

The single-arm phase II trial, registered as NCT05383716, investigated the efficacy and safety of a perioperative regimen for patients with resectable NSCLC. Participants received neoadjuvant pembrolizumab in combination with standard platinum-based chemotherapy, a combination that has shown significant promise in broader clinical settings. Following the induction phase, patients underwent definitive surgery, followed by adjuvant immunotherapy to target any residual microscopic disease. The primary endpoint of this investigation was the major pathological response (MPR), a surrogate marker that strongly correlates with long-term survival in lung cancer trials. Notably, the study enrolled 80 patients, with 55 ultimately proceeding to surgical intervention. Among those who underwent surgery, the MPR rate was an encouraging 37.5%, while the pathological complete response rate reached 26.3%. These findings highlight the potent antitumor activity of the pembrolizumab-chemotherapy combination before surgical resection. Additionally, the trial assessed the safety profile of this neoadjuvant approach, reporting that grade 3-4 treatment-related adverse events occurred in approximately 26.3% of the cohort. Importantly, these toxicities did not compromise the feasibility of surgical resection, suggesting that the regimen is effective and manageable in a controlled clinical environment.

Spatial Transcriptomics: Decoding the Immune Microenvironment

One of the most innovative aspects of this study involved the use of digital spatial profiling on resected tumors and paired draining lymph nodes. By examining 22 patients in detail, the researchers sought to identify transcriptomic pathways that distinguish responders from non-responders. Their findings revealed that tumors achieving an MPR were significantly enriched for pathways related to T-cell and B-cell activation. Specifically, these responding tumors exhibited a robust infiltration of CD8+ cytotoxic T cells, plasma cells, and T-follicular helper cells. These immune populations are critical for orchestrating a durable antitumor response and maintaining immune surveillance. In contrast, tumors that did not achieve a major pathological response demonstrated a starkly different transcriptomic profile. These non-MPR samples showed signatures of stress adaptation and active immune suppression, which likely contributed to treatment resistance. Furthermore, the analysis of paired lymph nodes provided additional context regarding the systemic immune response triggered by neoadjuvant chemoimmunotherapy in NSCLC. By comparing the microenvironment of the primary tumor with its draining nodes, the study highlighted how regional immune hubs interact during systemic therapy. This spatial resolution offers a more nuanced understanding of the immune microenvironment than traditional bulk sequencing methods.

Distinguishing LE Subtypes in Neoadjuvant Chemoimmunotherapy in NSCLC

Within the subset of tumors that responded favorably to treatment, researchers identified two distinct immune phenotypes: the myeloid-enriched (ME) subtype and the lymphoid-enriched (LE) subtype. These classifications represent fundamentally different ways the immune system interacts with the tumor during neoadjuvant chemoimmunotherapy in NSCLC. The LE subtype was characterized by a high density of B-cell and T-cell infiltrates, forming organized immune clusters that facilitate effective tumor killing. Consequently, patients with the LE phenotype experienced significantly improved survival outcomes in validation cohorts. Conversely, the ME subtype was dominated by myeloid cells, which are often associated with an immunosuppressive environment that hinders checkpoint inhibitors. Notably, patients with higher ME scores showed a trend toward poorer survival, even when initial tumor regression was observed. This distinction is crucial for clinical practice because it suggests that not all pathological responses are equal at the molecular level. Identifying these subtypes allows for a granular assessment of a patient's long-term prognosis. Moreover, the existence of these divergent phenotypes underscores the complexity of the tumor microenvironment and the need for biomarkers that look beyond simple cell counts. In light of this, the study focused on developing a practical tool for patient stratification.

Developing the 18-Gene Signature for Patient Stratification

To translate these complex spatial findings into a clinically useful tool, the researchers developed an 18-gene LE signature. This signature serves as a potential biomarker for predicting which patients derive the most benefit from adjuvant immunotherapy after surgery. By validating this signature across multiple cohorts, the study demonstrated its robust predictive power for survival and treatment response. Specifically, patients exhibiting high scores for the 18-gene LE signature were more likely to remain disease-free following their neoadjuvant and adjuvant treatment course. This discovery addresses a major clinical question in the management of resectable lung cancer: determining which patients require intensive adjuvant therapy. Currently, many patients receive adjuvant immunotherapy regardless of their initial response to neoadjuvant treatment. However, the LE signature could potentially identify a subgroup of patients who achieved an optimal immune state versus those requiring more aggressive interventions. Furthermore, the development of such a transcriptomic signature paves the way for future diagnostic assays integrated into routine pathology workflows. While further prospective validation is required, this 18-gene tool represents a significant step toward precision medicine in the perioperative setting for non-small cell lung cancer.

Clinical Safety and the Indian Healthcare Context

In the context of the Indian healthcare system, the implementation of neoadjuvant chemoimmunotherapy in NSCLC presents both opportunities and challenges. The trial's results confirm that the safety profile of pembrolizumab plus chemotherapy is manageable, with the majority of patients successfully proceeding to surgery. This is essential for Indian centers where surgical delays can sometimes occur due to logistical constraints. Moreover, the encouraging MPR rates suggest that this approach could significantly improve outcomes for the large number of Indian patients presenting with resectable disease. However, the adoption of spatial transcriptomics and complex gene signatures like the 18-gene LE profile may require investments in diagnostic infrastructure. Currently, many oncology centers in India are expanding their molecular pathology capabilities, and such biomarkers could eventually guide treatment decisions locally. Furthermore, multidisciplinary collaboration between thoracic surgeons, oncologists, and pathologists is more critical than ever. In conclusion, the study by Chen and colleagues provides a strong rationale for the use of perioperative immunotherapy in NSCLC while offering a glimpse into the future of spatial-based biomarkers. As we move forward, integrating these advanced insights into clinical practice will be key to improving the lives of lung cancer patients.

What defines a lymphoid-enriched (LE) subtype in resectable NSCLC?

The lymphoid-enriched (LE) subtype refers to a specific immune microenvironment architecture characterized by high infiltration of CD8+ T cells, B cells, and plasma cells. Furthermore, these tumors show increased activation of T-follicular helper cells and pathways associated with tertiary lymphoid structures. Research indicates that patients with this phenotype respond significantly better to neoadjuvant chemoimmunotherapy in NSCLC. Consequently, the LE subtype serves as a favorable prognostic indicator for pathological response and long-term survival outcomes.

How does spatial transcriptomics improve upon traditional biomarker testing?

Traditional biomarkers like PD-L1 often fail to capture the complex spatial relationships between immune cells and the tumor. Conversely, spatial transcriptomics allows clinicians to visualize exactly where immune cells are located relative to malignant cells. By mapping the tumor immune microenvironment, researchers can identify divergent phenotypes, such as myeloid-enriched or lymphoid-enriched regions. This high-resolution approach provides a more precise understanding of treatment resistance and response compared to standard bulk sequencing methods.

What are the safety implications of neoadjuvant pembrolizumab and chemotherapy?

In this phase II trial, neoadjuvant pembrolizumab combined with chemotherapy demonstrated a manageable safety profile. Grade 3-4 treatment-related adverse events occurred in approximately 26.3% of the participants. Notably, these toxicities did not typically prevent patients from undergoing their scheduled surgical procedures. Therefore, this multidisciplinary approach is considered feasible for patients with resectable non-small cell lung cancer. However, clinicians must maintain vigilance for immune-mediated reactions during the neoadjuvant and subsequent adjuvant phases of treatment.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Chen M et al. Divergent Tumor Immune Microenvironment and Response to Neoadjuvant Chemoimmunotherapy in Resectable Non-Small Cell Lung Cancer: A Single-Arm Phase II Trial. Clin Cancer Res. 2026 Jul 13. doi: 10.1158/1078-0432.CCR-25-4222. PMID: 42440361.

Wakelee H et al. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J Med. 2023;389(6):491-503. doi: 10.1056/NEJMoa2302983.

Heymach JV et al. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N Engl J Med. 2023;389(18):1672-1684. doi: 10.1056/NEJMoa2304875.